Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Russell Wada"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1080-1092 (2023)
Abstract Sparsentan is a single‐molecule dual endothelin angiotensin receptor antagonist (DEARA) currently under investigation as a treatment for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). A population pharmacokinetic (PK
Externí odkaz:
https://doaj.org/article/fa24d3487437408fb452433fbd197e18
Publikováno v:
Br J Clin Pharmacol
AIMS: In this exposure–response analysis, the dosing regimen for tildrakizumab, an antibody for treating moderate‐to‐severe chronic plaque psoriasis, was determined using data from 3 randomised controlled trials (P05495/NCT01225731: phase 2b, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f316f79af7bb7fa730259f4f07040b
https://doi.org/10.1111/bcp.14280
https://doi.org/10.1111/bcp.14280
Autor:
D. Russell Wada, Hanbin Li, Angelica Quartino, Bert L. Lum, Whitney P. Kirschbrown, Jin Y. Jin, Amit Garg, Ranvir Mangat
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The aim of the study was to characterize the population pharmacokinetics (PK) of the intravenous formulation of trastuzumab, assess the impact of patient and pathological covariates on trastuzumab PK, and perform simulations to support dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35d11ca72d3b571c792eb414e89d29dc
http://europepmc.org/articles/PMC6394489
http://europepmc.org/articles/PMC6394489
Publikováno v:
Anesthesiology. 128:943-952
Background Desirable product attributes for treatment of moderate-to-severe acute pain in many medically supervised settings are rapid onset and a route of administration not requiring intravenous access. The pharmacokinetic characteristics of sublin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c52b7c47c1c2e601bbc52b0f38b4e5
https://doi.org/10.1097/aln.0000000000002145
https://doi.org/10.1097/aln.0000000000002145
Autor:
Lin Zhang, Shanu Modi, Russell Wada, Hiroji Iwata, Ophelia Yin, Antoine Yver, Tushar Garimella, Kenji Tamura, Ian E. Krop, Junji Tsurutani, Kaku Saito, Caleb Lee, Masahiro Sugihara, Shunji Takahashi, Y. Kawasaki
Publikováno v:
Annals of Oncology. 30:vi84
Background In an ongoing phase 1 study (J101) of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2-targeted antibody drug conjugate, 5.4 and 6.4 mg/kg doses were recommended for expansion. The phase 2 DESTINY-Breast01 trial began with a dose-fin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97473384ae2ee2ddad63461fbd526f67
https://doi.org/10.1093/annonc/mdz339.009
https://doi.org/10.1093/annonc/mdz339.009
Autor:
Amos Baruch, Whittemore G. Tingley, Jin Y. Jin, Maya Leabman, D. Russell Wada, Kun Peng, Nageshwar Budha, John D. Davis
RG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low density lipoprotein cholesterol (LDLc) levels. RG7652 prevents degradation of the hepatic LDLc receptors by blocking PCSK9 binding and thereby resulting i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67d61c73da86d9fd10cb951ea4270ded
https://europepmc.org/articles/PMC4476990/
https://europepmc.org/articles/PMC4476990/
Publikováno v:
Clinical Pharmacokinetics. 44:1329-1342
Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesarta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33fc5fe3e9c7762b1bd53004f36fddd8
https://doi.org/10.2165/00003088-200544120-00011
https://doi.org/10.2165/00003088-200544120-00011
Autor:
Bert L. Lum, D. Russell Wada, Angelica Quartino, Hanbin Li, Whitney P. Kirschbrown, Amit Garg, Ranvir Mangat, Jin Y. Jin
Publikováno v:
Journal of Clinical Oncology. 35:2525-2525
2525 Background: The aim of this analysis was to develop a PPK model for IV trastuzumab (Herceptin), to assess the impact of patient covariates on PK, and perform simulations to support dosing recommendations. Methods: Serum trastuzumab concentration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb1fa48cfe7eb5389ed146e15b478a54
https://doi.org/10.1200/jco.2017.35.15_suppl.2525
https://doi.org/10.1200/jco.2017.35.15_suppl.2525
Autor:
Donald R. Stanski, Jörn Lötsch, Bhamini Ramaswamy, David R. Drover, Sujata Naidu, Martin S. Angst, D. Russell Wada
Publikováno v:
Anesthesiology. 94:63-73
Background The disposition kinetics of hydromorphone generally necessitates oral administration every 4 h of the conventional immediate-release tablet to provide sustained pain relief. This trial examined time course and magnitude of analgesia to exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f69713521459d814e88190934b9e968
https://doi.org/10.1097/00000542-200101000-00014
https://doi.org/10.1097/00000542-200101000-00014
Autor:
D. Russell Wada
Publikováno v:
Mathematical Biosciences. 146:75-88
In automatic feedback control of intravenous drug infusions, convergence to the setpoint is an important objective. This paper examines the stability of pharmacokinetic-pharmacodynamic models of patient response regulated with proportional integral f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1603f371c8e0264f751f12268ca977da
https://doi.org/10.1016/s0025-5564(97)00076-x
https://doi.org/10.1016/s0025-5564(97)00076-x